Navigation Links
Peptimmune Grants Major Pharmaceutical Company Exclusive Option to License PI-2301 for Multiple Sclerosis

CAMBRIDGE, Mass., Jan. 15 /PRNewswire/ -- Peptimmune, Inc. ("Peptimmune"), a privately held biotechnology company, announced today that it has granted Novartis (NYSE: NVS) an exclusive option to obtain exclusive worldwide rights to develop and commercialize PI-2301, Peptimmune's multiple sclerosis drug candidate. In a separate but related agreement, the MPM Bio IV NVS Strategic Fund L.P. made an equity investment in Peptimmune.

In the event that Novartis exercises the option to PI-2301, Novartis would assume the global clinical development, manufacturing, and marketing of PI-2301 and all associated costs. Peptimmune would receive payments upon the option exercise and upon successful completion of certain development, regulatory, and commercial milestones. These payments together could total more than $500 million. In addition, Peptimmune shall be eligible to receive royalties on product sales. Additional terms were not disclosed.

"We believe that Novartis represents an outstanding future partner for Peptimmune and the global development of PI-2301. This option agreement provides Peptimmune with access to both Novartis' world class development expertise and the necessary capital to invest in this proprietary product," said Thomas P. Mathers, President and CEO of Peptimmune.

Todd Foley, Managing Director at MPM Capital commented, "Peptimmune and its world-leading expertise in peptide copolymers represent an attractive investment opportunity."

About PI-2301

PI-2301 is a peptide copolymer developed using Peptimmune's novel platform peptide chemistry. PI-2301 is designed to enhance the regulatory response of the immune system, thereby controlling the pathogenic autoimmune response in certain diseases. PI-2301 is currently in Phase 1b development by Peptimmune.

About Peptimmune (

Peptimmune is a clinical stage biotechnology company developing peptide and peptide-copolymer therapeutics for the treatment of CNS and Autoimmune disorders. These therapies target MHC Class II molecules and modulating immune responses. Founded in 2002 and located in Cambridge, MA USA, the Company is led by an experienced management team and exploits its proprietary DEEP(TM) Technology to design peptides and peptide mixtures.

SOURCE Peptimmune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Peptimmune Announces the Second Close of Series D Private Financing
2. Tufts receives NIH grant to study obesity prevention in new immigrants
3. Floridas Uninsured and Underinsured to Benefit from Statewide Grants
4. Nemours Center for Childhood Cancer Research Receives Over $1 Million in Grants for Cancer Research in 2008
5. Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company License to Certain Alzheimers Patents and Patent Applications
6. The National Parkinson Foundation Awards Five Grants for the Falls Prevention Initiative
7. Life Sciences Discovery awards health research program grants
8. Blue Cross Foundation Awards $660,000 in Grants to Improve Community Health
9. FDA Grants NeoVistas Request to Utilize Novel Wet AMD Treatment in Compassionate Case
10. UnitedHealth Group Grants to Help Students and Educators Combat Childhood Obesity
11. Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity
Post Your Comments:
(Date:11/30/2015)... (PRWEB) , ... November 30, ... ... (AIS) is pleased to announce the speakers for “Value-Based Payer-Provider Partnerships: Three ... learned from three innovative value-based care arrangements: Essentia Health and UCare, MissionPoint ...
(Date:11/30/2015)... ... November 30, 2015 , ... Vasont Systems, a top component ... (VUI) extension unites with Syncro Soft’s latest software update, oXygen XML editor Version ... with the latest release of oXygen® XML editor and the Vasont® CCMS. ...
(Date:11/30/2015)... ... November 30, 2015 , ... Scott Newman MD, FACS ... select few plastic surgeons in the New York City area to utilize the ... world’s first heat-induced laser treatment for fat loss in the abdomen, flanks, and ...
(Date:11/30/2015)... ... November 30, 2015 , ... TransPack Volume 6 features 30 customizable ... from scrolling web-styled transitions to wipes with blur & drop shadow options. Utilize ... Seamlessly transition from one clip to the next with TransPack's easily customizable styles. ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... strategic partnership at the Radiological Society of North America (RSNA) 2015 conference. ... providers of cutting-edge dictation and speech-enabled documentation software, announced their partnership today ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... iCAD, Inc. (Nasdaq: ICAD ) ... solutions for advanced image analysis and workflow tools ... Radiological Society of North American (RSNA) 2015 Annual ... November 29 to December 4, 2015. The company ... automated breast density assessment solution, PowerLook® Advanced Mammography ...
(Date:11/30/2015)... SALT LAKE CITY , Nov. 30, 2015 ... Systems (NYSE: VAR ) will exhibit a broader array ... meeting of the Radiological Society of North America ... The Varian exhibit at the meeting will feature X-ray components ... Cardinal CT tube, a line of products from Varian,s Claymount ...
(Date:11/30/2015)... Nov. 30, 2015  Novartis will demonstrate the strength ... th American Society of Hematology (ASH) Annual Meeting. ... as well as supportive care, including key findings in ... cell therapies. The ASH Annual Meeting will be held ... Novartis Oncology . "We will be presenting ...
Breaking Medicine Technology: